ReviewCureus2026
Comparative Efficacy of Rectal Diclofenac and Rectal Indomethacin in Preventing Post-endoscopic Retrograde Cholangiopancreatography Pancreatitis: A Systematic Review.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP) is the most frequent complication of endoscopic retrograde cholangiopancreatography (ERCP) and is a major source of ERCP procedure-related morbidity. Nonsteroidal anti-inflammatory drugs (NSAIDs) such as diclofenac and indomethacin are commonly used for PEP prophylaxis because of their anti-inflammatory properties. The aim of the present systematic review was to compare the efficacy of rectal diclofenac versus rectal indomethacin in preventing PEP. The review was conducted using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines, and studies were identified through a comprehensive search of databases covering the period from 2019 to 2025. Nine studies were included. The findings indicate that both rectal diclofenac and rectal indomethacin are effective prophylactic agents and significantly reduce the incidence of PEP. In conclusion, the available evidence supports the routine use of either rectal diclofenac or rectal indomethacin to prevent post-ERCP pancreatitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.